Micro Labs, Karnataka's formulation and active pharma ingredient (API) major, has crossed Rs 1,000 crore turnover for the financial year 2007-08. The company's exports touched to Rs 325 crore. There was a 20 per cent growth rate in dollar terms.

The company grew in all the therapeutic segments which cover cardiovascular, antibiotics, anti-diabetics, dermatology, ophthalmology, neuro-psychiatry, gastro-intestinal and pain killers marketed through 14 specialty divisions. Two of the divisions: general and specialty, which are Micro Main and Carsyon (cardiology), have already crossed the Rs 100 crore mark.

As part of its expansions in terms of Greenfield projects, Micro Labs has allocated Rs 160 crore to set-up two research and development centres in Mumbai and Bangalore. The company is investing Rs 60 crore in Mumbai centre and Rs 100 crore in Bangalore unit. The Mumbai centre is likely to be operational by July this year and the construction work at Bangalore will also start from July, informed Dilip Surana, managing director Micro Labs.

According to the latest secondary sales data released by ORG-IMS, an independent market research organization, reflects the Micro Labs regained position into the top 20 companies' group with a growth of 25 per cent for two months ending February, 2008.

Rationalization of product, promotion mix, production related economies of scale and e-business connectivity along with its sales force have contributed to the growth.

Aggressive plans are in the offing to accelerate sales momentum to penetrate the market through a slew of brands which have been identified for major thrust for the future, stated G Jairaj, vice president, marketing and corporate communications, Micro Labs.